Department of Pharmacology and Therapeutics
Department
| Associate Professor | Junji Saruwatari junsaru(at mark)gpo.kumamoto-u.ac.jp |
|---|---|
| Assistant Professor | Kentarou Oniki oniken(at mark)kumamoto-u.ac.jp |
Research themes
[Names and Summaries of Research Projects]
- Development of Designs for the Personalized Dispensation of Medicine Based on Pharmacogenetics
- Research Related to Polymorphisms of Drug-Metabolizing Enzymes, Disease Susceptibility, and the Expression of Side-Effects
- Research Related to Differences in Side Effects Due to Gender and Risk Stratification Regarding Lifestyle Diseases
- Clinical Pharmacological Research Related to Safety and New Applications of Drug Therapy
- Clinical Applications of New Methods for Measuring Free Radicals
Our research seeks to advance the field of individualized treatment by discovering the relationship between factors which vary by the patient including drug-metabolizing enzymes, polymorphisms, and others (gender, history of smoking, concomitant drugs, etc.) and medical factors such as pharmacokinetics, pharmacodynamics, disease susceptibility, and pathology.
We focus our research on the design of appropriate dosages for individual patients, how side-effects of medication are expressed, and risk stratification for lifestyle diseases. Specifically, 1.
We use population pharmacokinetic and pharmacodynamic analysis to estimate the ideal dosage of medicine for neuropsychiatric disorders, according to the patient's background including his or her genetic information. In addition, 2.
We are conducting research with the goal of creating gene diagnoses panels which use multivariate analysis of multiple candidate genes to stratify the risk of outbreak of diabetes, fatty liver, and other lifestyle diseases and which will help improve the lifestyles of patients in order to prevent the onset or progression of these diseases. Furthermore, 3.
While there are numerous reports of a gender gap in the expression of medicinal side-effects, the details of such a difference are not well understood.
Therefore, we at the Kumamoto Pharmaceutical Association Drug Event Monitoring (DEM) Project have received the data available and are investigating the gender gap of side-effects which have been observed in DDP-4 inhibitors and various other drugs which are in use.
Research initiatives at our laboratory related to personalized dosage designs of drugs and risk stratification for lifestyle diseases
